Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Q3 2025 value amounting to $11.3 million.

  • Catalyst Pharmaceuticals' Gains from Investment Securities fell 1302.16% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 1302.16%. This contributed to the annual value of $13.1 million for FY2024, which is 776.37% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Gains from Investment Securities of $11.3 million as of Q3 2025, which was down 1302.16% from $12.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $53.0 million during Q4 2024, with a 5-year trough of -$76000.0 in Q1 2021.
  • Its 5-year average for Gains from Investment Securities is $11.3 million, with a median of $11.3 million in 2025.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Gains from Investment Securities tumbled by 20270.27% in 2021 and then skyrocketed by 2635115.38% in 2024.
  • Catalyst Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $136000.0 in 2021, then surged by 22781.62% to $31.1 million in 2022, then plummeted by 30.15% to $21.7 million in 2023, then skyrocketed by 143.95% to $53.0 million in 2024, then crashed by 78.63% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in Q3 2025, $12.2 million for Q2 2025, and $12.6 million during Q1 2025.